Skip Navigation


Annals of Oncology Advance Access originally published online on January 29, 2007
Annals of Oncology 2007 18(7):1152-1158; doi:10.1093/annonc/mdl476
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
18/7/1152    most recent
mdl476v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Chan, A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chan, A
Related Collections
Right arrow 2007 - Review Articles
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

reviews

A review of the use of trastuzumab (Herceptin®) plus vinorelbine in metastatic breast cancer

A Chan*

Mount Breast Group, Mount Hospital, Perth, Australia

* Correspondence to: Dr A. Chan, Medical Oncologist, Suite 41, 146 Mounts Bay Road, Mount Hospital, Perth 6000, Australia. Tel: +61-8-9481-4522; Fax: +61-8-9481-4544; E-mail: arlene.chan{at}bigpond.com

The combination of trastuzumab (Herceptin®) and vinorelbine (Navelbine®) in the treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) is valuable for several reasons. There is proven synergism of these agents in preclinical models, both agents are well tolerated and there is minimal overlapping toxicity. This article reviews clinical experience with trastuzumab and vinorelbine from phase II/III trials including >450 assessable patients. Results across the trials show objective response rates for the combination in the range of 44%–86% (51%–86% as first-line treatment) and a median duration of response of 10–17.5 months. Approximately 50% of patients experience grade 3/4 neutropenia, which is of short duration and manageable. Symptomatic cardiac events are infrequent (seven episodes of grade 3 toxicity across all trials). Overall, trastuzumab–vinorelbine combination therapy offers patients with HER2-positive MBC, an effective and well-tolerated treatment that is suitable for prolonged duration of use.

Key words: adverse effects, breast neoplasms, combination drug therapy, trastuzumab, treatment outcome, vinorelbine

Received for publication August 15, 2006. Revision received November 13, 2006. Accepted for publication November 27, 2006.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 The OncologistHome page
A. Morabito, M. C. Piccirillo, K. Monaco, C. Pacilio, F. Nuzzo, P. Chiodini, C. Gallo, A. de Matteis, F. Perrone, and NCI Naples Breast Cancer Group
First-Line Chemotherapy for HER-2 Negative Metastatic Breast Cancer Patients Who Received Anthracyclines as Adjuvant Treatment
Oncologist, November 1, 2007; 12(11): 1288 - 1298.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.